GlassScriptPhysician profile
Colin W Sumida
NPI 1174572119
$3,107.88
in general payments reported to CMS, 2019-2025
28 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $86.63 · 2021: $347 · 2022: $1,404 · 2023: $359 · 2024: $427 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventric Diagnostics, INC. | $905.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $279.90 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.66 | 2021-2025 | Lifevest |
| Pfizer INC. | $249.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.69 | 2019-2024 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $152.58 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.73 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $100.11 | 2019-2024 | Andexxa |
| Amgen INC. | $92.17 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $90.39 | 2021-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $89.29 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $88.97 | 2019-2021 | |
| Boston Scientific Corporation | $67.07 | 2023-2025 | General - Therapies |
| Sanofi-Aventis U.S. LLC | $63.23 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $40.61 | 2023 | Assure Wcd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $40.52 | 2021-2022 | |
| Edwards Lifesciences Corporation | $39.79 | 2025 | Pascal |
| Amarin Pharma, INC. | $35.59 | 2021-2022 | |
| Heartflow, INC. | $28.34 | 2025 | |
| Abbott Laboratories | $26.74 | 2023 | Cardiomems |
| Avinger INC. | $24.66 | 2023 | Pantheris |
| Scpharmaceuticals INC. | $23.52 | 2024 | |
| Chiesi USA, INC. | $22.14 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.58 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.14 | 2022 | |
| Glaxosmithkline, LLC. | $14.84 | 2025 | Shingrix |
| Medtronic, INC. | $13.15 | 2022 | |
| Medtronic Vascular, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Sumida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.